Search results for "eGFR"

showing 10 items of 150 documents

Anklage, Nachdenken und Idealisierung

2013

fuite[SHS.LITT] Humanities and Social Sciences/LiteratureSiegfried Lenzanciennes Provinces de l'Est allemandesmémoire[SHS.HIST] Humanities and Social Sciences/Historyexpulsionlittérature sur les anciennes provinces de l'est allemandesGregor von RezzoriHorst Bienek +
researchProduct

Acetic Acid Mediated for One-Pot Synthesis of Novel Pyrazolyl s-Triazine Derivatives for the Targeted Therapy of Triple-Negative Breast Tumor Cells (…

2022

Here, we described the synthesis of novel pyrazole-s-triazine derivatives via an easy one-pot procedure for the reaction of β-dicarbonyl compounds (ethylacetoacetate, 5,5-dimethyl-1,3-cyclohexadione or 1,3-cyclohexadionone) with N,N-dimethylformamide dimethylacetal, followed by addition of 2-hydrazinyl-4,6-disubstituted-s-triazine either in ethanol-acetic acid or neat acetic acid to afford a novel pyrazole and pyrazole-fused cycloalkanone systems. The synthetic protocol proved to be efficient, with a shorter reaction time and high chemical yield with broad substrates. The new pyrazolyl-s-triazine derivatives were tested against the following cell lines: MCF-7 (breast cancer); MDA-MB-231 (tr…

kemiallinen synteesiDMF-DMAlääkekemiabioaktiiviset yhdisteetAnticancer profilePharmaceutical ScienceApoptosisOne-pot synthesisheterosykliset yhdisteetPyrazolyl-s-triazineone-pot synthesis; DMF-DMA; pyrazolyl-<i>s</i>-triazine; anticancer profile; EGFR/PI3K/AKT/mTOR; apoptosisinhibiittoritEGFR/PI3K/AKT/mTOR
researchProduct

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

2011

Introduction: The use of monoclonal antibodies is one of the strategies for targeting the specific key points of the main pathways of cancer growth and survival, but only a few antibodies have offered a clear clinical benefit in the treatment of non-haematological malignancies. Areas covered: This review summarizes the general properties of monoclonal antibodies, including structure, nomenclature and production techniques. The antibodies approved for use in clinical practice for the treatment of non-haematological tumors and those antibodies still being developed in this setting are briefly described. The types of antibody fragments are also reported. Expert opinion: Monoclonal antibodies w…

medicine.drug_classSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryMonoclonal antibodyAntibody fragmentsNeoplasm ProteinNeoplasmsDrug DiscoveryImmunoglobulin FragmentmedicineAnimalsHumansImmunoglobulin FragmentsAnti-EGFRPharmacologyChemotherapyMonoclonal antibodiebiologybusiness.industryAnimalDrug Discovery3003 Pharmaceutical ScienceAnti-VEGFCancerAntibodies MonoclonalImmunotherapymedicine.diseaseAntibody fragmentNeoplasm ProteinsAnti-HER2Clinical PracticeTreatment OutcomeExpert opinionImmunologybiology.proteinNeoplasmMonoclonal antibodiesImmunotherapyAnti-EGFR; Anti-HER2; Anti-VEGF; Antibody fragments; Monoclonal antibodiesAntibodybusinessHuman
researchProduct

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

2015

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyCardiomyopathyRenal functionSE Standard errorLeft ventricular hypertrophyBiochemistryLVH Left ventricular hypertrophyLong-term effectivenessEndocrinologyGeneticsMedicineMDRD Modification of Diet in Renal Diseaselcsh:QH301-705.5Molecular BiologyAgalsidase alfaeGFR Estimated glomerular filtration rateFabry diseaselcsh:R5-920CI Confidence intervalbusiness.industryEnzyme replacement therapymedicine.diseaseEgfr Estimated glomerular filtration rateFabry diseaseSurgeryARB Angiotensin receptor blockerSEM Standard error of the meanStandard errorlcsh:Biology (General)SI:TherapyEnzyme replacement therapyCohortFOS Fabry Outcome SurveyLVMI Left ventricular mass indexed to heightlcsh:Medicine (General)businessACEI Angiotensin-converting enzyme inhibitorAgalsidase alfaERT Enzyme replacement therapyMolecular Genetics and Metabolism Reports
researchProduct

Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the…

2022

Abstract Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres.…

medicine.medical_specialtyReduced doseColorectal cancerLeucovorinCetuximabNeutropeniaGastroenterologyFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPanitumumabDoublet chemotherapyAnti-EGFRAgedCetuximabMetastatic colorectal cancerRectal Neoplasmsbusiness.industryPanitumumabAnti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patientsExanthemamedicine.diseaseRashVulnerable older patients.OncologyColonic NeoplasmsFOLFIRIFluorouracilGeriatrics and Gerontologymedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Geriatric Oncology
researchProduct

Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Pr…

2021

Background: Serum uric acid predicts the onset and progression of kidney disease, and the occurrence of cardiovascular and all-cause mortality. Nevertheless, it is unclear which is the appropriate definition of hyperuricemia in presence of chronic kidney disease (CKD). Our goal was to study the independent impact of uric acid and CKD on mortality.Methods: We retrospectively investigated 21,963 patients from the URRAH study database. Hyperuricemia was defined on the basis of outcome specific cut-offs separately identified by ROC curves according to eGFR strata. The primary endpoints were cardiovascular and all-cause mortality.Results: After a mean follow-up of 9.8 year, there were 1,582 (7.2…

medicine.medical_specialtyhyperuricemiaCardiovascular Medicineurologic and male genital diseasesGastroenterologyalbuminuriachemistry.chemical_compoundcardiovascular mortalityInternal medicinemedicineeGFRDiseases of the circulatory (Cardiovascular) systemHyperuricemiaRisk factorOriginal Researchbusiness.industryIncidence (epidemiology)Confoundingalbuminuria; all-cause mortality; cardiovascular mortality; eGFR; hyperuricemiahyperuricemia eGFR albuminuria cardiovascular mortality all-cause mortalitymedicine.diseasechemistryQuartileRC666-701AlbuminuriaUric acidall-cause mortalitymedicine.symptomCardiology and Cardiovascular MedicinebusinessKidney disease
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Impacto del miRNA-200c sobre el mecanismo de migración celular en el glioblastoma.Relación con los patrones de amplificación de EGFR.

2016

El Glioblastoma Multiforme (GB), la neoplasia primaria del SNC más importante en adultos, por su frecuencia y agresividad, se muestra como paradigmática de los procesos de infiltración y angiogénesis en las neoplasias. Su localización en el sistema nerviosos central, su alta capacidad invasiva y las consecuencias de una angiogénesis displasica hacen del GB una enfermedad neoplásicas altamente invalidante y de evolución fatal, en la que las distintas acciones terapéuticas se muestran ineficaces. Este trabajo realiza un estudio clínico, morfológico ,genético y epigenético de 46 casos de GB primarios. Se describe un grupo de miRNAs no descritos anteriormente en el GB. Se estableció la correlac…

migraciónmirna-200cglioblastomaamplificación egfr
researchProduct

The Value of Liquid Biopsies for Guiding Therapy Decisions in Non-small Cell Lung Cancer

2019

personalized therapysyöpähoidotEGFRprecision medicinebiopsiaDNActDNAdiagnostiikkata3111ta3122verenkiertoNSCLCkeuhkosyöpäsyöpäsolutmarkkeritcancerFrontiers in Oncology
researchProduct

Katsomisen hierarkiat ja kuinka niitä murretaan : valokuvateoksen rooli suomalaisessa yhteisötaiteessa

2012

Tutkielmassa tarkastellaan taideteoksen roolia suomalaisessa yhteisötaiteessa saksalaisen kriittisen koulukunnan näkökulmasta. Yhteisötaide on 1990-luvulta alkaen vahvistunut taidemuoto, jossa taiteilija työskentelee yhdessä tietyn ihmisryhmän kanssa. Ensimmäisiä yhteisötaideprojekteja Suomessa toteutettiin 1970-luvulla lähiöissä. 2000-luvulla yhteisötaiteessa on alettu käyttää ilmaisumuotona valokuvaa. Tässä tutkielmassa esimerkkeinä käytetään teoksia Maailman ihanin tyttö, Lempipaikka ja Be your enemy. Tutkijoista esimerkkeinä käytetään Mika Hannulan, Helena Sederholmin ja Lea Kantosen teorioita ja taiteilijoista Miina Savolaisen, Teemu Mäen ja Lea Kantosen näkökulmia. Tavoitteena on osoi…

valokuvataideyhteisötaidetaideteoksetKracauer SiegfriedAdorno Theodor WBenjamin WalterFreire Pauloroolit
researchProduct